• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
ACOR

ACOR

Acorda Therapeutics, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD0.66

-0.21 (-24.02%)

Company Profile

CEO

Ron Cohen

IPO Date

2006-02-10

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.78

Prev. Close

$0.87

Day Low

$0.61

Day High

$0.85

52W Low

$0.61

52W High

$24.20

Market Cap

$0.00B

Volume

0.32M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

37.4%

Avg Negative

3.2%

Avg Neutral

59.1%

News Feed

Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

Business Wire·7/30/2021·↓ negative

Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know

Zacks Investment Research·7/27/2021·↑ positive

Acorda Therapeutics Continues To Maneuver For A Turnaround

Seeking Alpha·7/24/2021·↑ positive

ACOR Stock Increases Over 40% Pre-Market: Why It Happened

Pulse2·7/23/2021·↑ positive

Acorda Therapeutics Shares Gains On Spain Distribution Pact For Parkinson's Med

Benzinga·7/23/2021·↑ positive

ACOR Stock Increased 24.67% After Hours: Why It Happened

Pulse2·7/23/2021·↑ positive

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive

Acorda Therapeutics: Buying Before The Coast Is Clear

Seeking Alpha·4/29/2021·↑ positive

Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

Business Wire·4/29/2021·↓ negative